---

Market Overview

---

The global synthetic biology market reached a value of USD 10.13 billion in 2021 and is estimated to reach USD 38.73 billion by 2027, with a compound annual growth rate (CAGR) of 25% during the forecast period from 2022 to 2027. Synthetic biology is an emerging interdisciplinary field that applies engineering principles to biology. Its goal is to design and manufacture biological components and systems that do not exist in nature. By combining DNA synthesis and genetic knowledge, researchers can rapidly create cataloged DNA sequences and assemble them into new genomes. This advancement in DNA synthesis speed and cost has enabled scientists to develop advanced biofuels, bioproducts, renewable chemicals, pharmaceutical intermediates, fine chemicals, and food ingredients.

Industrial biotechnology plays a crucial role in enhancing natural biological processes to produce enzymes, chemicals, polymers, and everyday necessities such as food and fuel. Through the study of microorganism genomes, scientists have identified biological processes that can replace traditional chemical reactions, leading to cleaner manufacturing processes and reduced production steps. Industrial biotechnology innovations are gradually replacing traditional petrochemical manufacturing processes, as they offer cost reduction, lower pollution and carbon dioxide emissions, and increased profitability.

Synthetic biology encompasses various approaches, including the design of gene and protein circuits using standard biological parts, the development of synthetic genetic codes, and the creation of artificial cells and organisms. These approaches provide opportunities for applying knowledge in different branches of science and technology. Redesigning existing biological parts expands the range of functions that biological processes can perform. Synthetic biology opens up new possibilities and allows for the creation of innovative biological solutions by implementing new functions through technology platforms or upgraded physical structures.

Synthetic biology offers modern engineering approaches to develop new biological systems or redesign existing ones for practical applications. One notable application is CAR-T therapy, which offers advantages not found in other cancer treatments.

There is a significant influx of investments in synthetic biology start-ups due to their innovative market solutions. Numerous pipeline products are being developed in this field. Countries such as Germany, China, and Italy are progressing towards mature markets, while regions like Africa have a limited presence of companies and academic institutions in synthetic biology. India is in the early stages of adopting synthetic biology. In the current scenario, there are more opportunities than challenges in synthetic biology, although ethical issues still need to be addressed.

Synthetic biology has the potential to revolutionize food production, source materials, and medicine. Biotechnology, pharmaceutical, and agriculture companies have been at the forefront of applying synthetic biology tools developed between 2000 and 2021, with many products already available or in the pipeline. Over the next decade, there will be an increasing number of products that leverage engineered biology to achieve superior performance and affordability. Synthetic biology is already making a significant impact on life sciences, pharmaceuticals, and industrial applications.

In North America, the market’s growth is driven by factors such as the wide range of synthetic biology applications, increased research and development funding and initiatives, declining costs of genome sequencing and synthesis, and high investments in the market. The synthetic biology market in North America is expanding rapidly in industrial, food and agriculture, and environmental sectors. The region boasts advanced genomic labs and research centers that collaborate with pharmaceutical and biotech companies worldwide. Additionally, North America has a substantial population engaged in agriculture, with a significant area of land dedicated to organic farming and the cultivation of genetically modified crops.

Europe has seen multiple research projects in the life sciences field across different European countries. The region ranks second, after North America, in genome sequencing for cell and gene therapy. The market players in Europe focus on investing in research and development, leading to intense competition among established and emerging players.

In the Asia-Pacific (APAC) region, stringent regulatory requirements and high costs of technology infrastructure maintenance pose challenges to market growth. However, government support in many Asian countries is driving the development of biopharmaceuticals. Developing countries in APAC are expanding their biosimilars manufacturing capabilities due to lower per capita spending requirements. Synthetic biology is also being adopted in vaccine manufacturing to improve yields and reduce production costs. The agri-food sector in five Asian countries is receiving significant investment, positioning them as key markets for synthetic biology.

Latin America, comprised of developing and underdeveloped countries, has moderate usage of advanced biotechnology products like synthetic biology due to less stringent regulatory requirements. However, the region is witnessing increased research activities and a growing focus on building sustainable environmental conditions using synthetic biology tools. Latin America plays a vital role in the food processing market, with expanding research labs and processing industries. It is a major exporter of food and agricultural commodities.

In the Middle East and Africa, synthetic biology offers opportunities to tackle challenges such as malnutrition, diseases, hunger, and pollution. African countries are establishing foundations and organizations to unify efforts among scientists, researchers, farmers, and policymakers, positively impacting communities. In the Middle East, advancements in environmentally friendly products contribute to pollution reduction. Additionally, research exploring new products is underway in this region.

---

Market Segmentation

---

The market is segmented based on various factors, including tools, technology, application, end-user, and geography.

Segmentation by Tools
Oligonucleotides and Synthetic DNA
Enzymes
Cloning Technology Kits
Xeno-Nucleic Acids
Chassis Organisms

Segmentation by Technology
Enabling Technology
Enabled Technology

Segmentation by Application
Healthcare Application
Industrial Application
Food & Agriculture Applications
Environmental Application

Segmentation by End-user
Academic/Research Institutes & Laboratories
Pharma & Biotech Companies
Others

Segmentation by Geography
North America – US, Canada
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan, India, South Korea, Australia
Latin America – Brazil, Mexico, Argentina
Middle East & Africa – South Africa, Saudi Arabia, Turkey

Synthetic biology involves the (re-)design of existing life forms or the creation of new ones in the form of products. It sets itself apart from traditional molecular and cellular biology by focusing on the development and construction of tools that can be modeled, understood, and optimized to meet specific performance criteria. These tools, which include smaller parts and devices, are then integrated into larger systems to solve problems or achieve better outcomes. In the realm of synthetic biology, the synthetic DNA market has proven to be a significant revenue generator, particularly in areas such as data storage, product labeling, and signal processing, where it serves as an alternative to device-based technology.

Over the forecast period, the enzymes market is expected to grow at a compound annual growth rate (CAGR) of approximately 26%. Enzymes derived from microorganisms show great potential in waste management, contributing to the development of environmentally friendly practices. Their utilization across various industries allows for higher-quality production with minimal environmental pollution and accelerated reaction rates, thus enhancing cost-efficiency.

To ensure accessibility for research, continuous development of enabling and enabled technologies is essential for synthetic biology applications. The rapid emergence of enabling technologies has led to their application in diverse projects related to healthcare, industry, food and agriculture, and large-scale environmental initiatives. These enabling technologies have gained widespread acceptance in the field of synthetic biology.

Synthetic biology finds extensive applications in biomedicine, therapeutics, diagnostics, and advanced therapies. The food and agriculture sector also benefits from genome-based research, which aids in the development of new viable products and the resolution of contemporary challenges. By leveraging synthetic biology tools, technology, and engineering principles to transform biology, advancements are made in the production of bio-based therapies, chemicals, materials, fresh food, and energy sources, ultimately improving and safeguarding the natural environment. Synthetic biology’s broad applicability impacts various fields and contributes to the betterment of human lives.

Synthetic biology enjoys wide acceptance among end-users. Academic and research institutes, as well as laboratories, play a pivotal role in studying synthetic biology tools and techniques. Through their research, a deeper understanding of these tools and technologies is obtained, along with insights into their potential impact on specific segments or sectors. The healthcare industry has witnessed significant impacts resulting from the emergence and advancements in synthetic biology. Pharmaceutical and biotechnology companies serve as hubs for research investments and the commercialization of synthetic biology products. Major players in the market raise funds for research purposes and engage in collaborations or acquisitions with other institutions.

---

Competitive Landscape

---

Key companies profiled in this report include Agilent Technologies, Codexis, Eurofins Scientific, Illumina, Novozymes, Thermo Fisher Scientific, Amyris, ATUM, Bio-Rad Laboratories, Creative Biogene, Creative Enzymes, Cyrus Biotechnology, Editas Medicine, Genomatica, Genscript, Ginkgo Bioworks, Integrated DNA Technologies, Lucigen, Moderna, New England Biolabs, OriGene Technologies, Precigen, Sentebiolab, SynbiCITE, Synthego, Tessera Therapeutics, Viridos.

---

Key Questions Answered

---

What is the market value of the global synthetic biology market?

The global synthetic biology market had a valuation of USD 10.13 billion in 2021 and is projected to reach USD 38.73 billion by 2027.

What is the estimated growth rate of the global synthetic biology market?

The global synthetic biology market is expected to experience a compound annual growth rate (CAGR) of 25.05% during the period of 2022-2027.

Which region holds the largest share in the global synthetic biology market?

North America holds the largest share in the global synthetic biology market.

Who are the key players in the global synthetic biology market?

Key players in the global synthetic biology market include Agilent Technologies, Codexis, Eurofins Scientific, Illumina, Novozymes, and Thermo Fisher Scientific.

What are the growth factors driving the global synthetic biology market?

The major growth factors driving the global synthetic biology market include increased investments, strategic collaborations and acquisitions, the development of multifunctional products, and the introduction of transformative technologies in agriculture.